{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T06:29:19Z","timestamp":1762324159459,"version":"3.37.3"},"reference-count":22,"publisher":"BMJ","issue":"5","funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Br J Ophthalmol"],"published-print":{"date-parts":[[2018,5]]},"abstract":"<jats:sec><jats:title>Background\/aims<\/jats:title><jats:p>The WHO recommends 3\u20135 years of annual mass azithromycin distribution with at least 80% treatment coverage to districts with active trachoma prevalence over 10% among children. Here, we assess the efficacy of expanding the coverage target to at least 90% for trachoma control in a mesoendemic region of Niger.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Twenty-four communities were randomised to a single day of azithromycin distribution with a coverage target of 80% of the community or up to 4 days of treatment, aiming for greater than 90% coverage. Distributions were annual and individuals above 6 months of age were treated. Children under 5 years of age were monitored for ocular chlamydia infection and active trachoma.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>At baseline, ocular chlamydia prevalence was 20.5% (95% CI 9.8% to 31.2%) in the standard coverage arm and 21.9% (95% CI 11.3% to 32.5%) in the enhanced coverage arm, which reduced to 4.6% (95% CI 0% to 9.5%, p=0.008) and 7.1% (95% CI 2.7% to 11.4%, p&lt;0.001) at 36 months, respectively. There was no significant difference in 36-month ocular chlamydia prevalence between the two arms (p=0.21). There was no difference in the rate of decline in ocular chlamydia between the two arms in a repeated measures model (p=0.80).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>For annual mass azithromycin distribution programme to an entire community, there may be no additional benefit of increasing antibiotic coverage above the WHO\u2019s 80% target.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial registration number<\/jats:title><jats:p>NCT00792922, post-results.<\/jats:p><\/jats:sec>","DOI":"10.1136\/bjophthalmol-2017-310916","type":"journal-article","created":{"date-parts":[[2017,9,12]],"date-time":"2017-09-12T00:40:26Z","timestamp":1505176826000},"page":"680-686","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":17,"title":["Effectiveness of expanding annual mass azithromycin distribution treatment coverage for trachoma in Niger: a cluster randomised trial"],"prefix":"10.1136","volume":"102","clinical-trial-number":[{"clinical-trial-number":"nct00792922","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Abdou","family":"Amza","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boubacar","family":"Kadri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beido","family":"Nassirou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sun Y","family":"Cotter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole E","family":"Stoller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheila K","family":"West","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robin L","family":"Bailey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Travis C","family":"Porco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce D","family":"Gaynor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeremy D","family":"Keenan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas M","family":"Lietman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine E","family":"Oldenburg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2017,9,11]]},"reference":[{"key":"2020050713011097000_102.5.680.1","unstructured":"World Health Organization. Report of the 17th meeting of the WHO alliance for the global elimination of blinding trachoma. Geneva 2013:1\u201356."},{"key":"2020050713011097000_102.5.680.2","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1001\/jamaophthalmol.2013.2356","article-title":"Can we stop mass drug administration prior to 3 annual rounds in communities with low prevalence of trachoma?: PRET Ziada trial results","volume":"131","author":"Yohannan","year":"2013","journal-title":"JAMA Ophthalmol"},{"key":"2020050713011097000_102.5.680.3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0000376"},{"key":"2020050713011097000_102.5.680.4","doi-asserted-by":"publisher","DOI":"10.1001\/jama.292.6.721"},{"key":"2020050713011097000_102.5.680.5","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/S0140-6736(09)60323-8","article-title":"Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster-randomised trial","volume":"373","author":"House","year":"2009","journal-title":"The Lancet"},{"key":"2020050713011097000_102.5.680.6","doi-asserted-by":"publisher","DOI":"10.1086\/424747"},{"key":"2020050713011097000_102.5.680.7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0002415"},{"key":"2020050713011097000_102.5.680.8","doi-asserted-by":"publisher","DOI":"10.3109\/09286586.2010.545500"},{"key":"2020050713011097000_102.5.680.9","doi-asserted-by":"crossref","first-page":"e2115","DOI":"10.1371\/journal.pntd.0002115","article-title":"Mass treatment with azithromycin for trachoma: when is one round enough? Results from the PRET Trial in the Gambia","volume":"7","author":"Harding-Esch","year":"2013","journal-title":"PLoS Negl Trop Dis"},{"key":"2020050713011097000_102.5.680.10","doi-asserted-by":"crossref","unstructured":"Amza A , Kadri B , Nassirou B , et al . A cluster-randomized trial to assess the efficacy of targeting trachoma treatment to children. Clin Infect Dis 2016.","DOI":"10.1093\/cid\/ciw810"},{"key":"2020050713011097000_102.5.680.11","first-page":"477","article-title":"A simple system for the assessment of trachoma and its complications","volume":"65","author":"Thylefors","year":"1987","journal-title":"Bull World Health Organ"},{"key":"2020050713011097000_102.5.680.12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0001586"},{"key":"2020050713011097000_102.5.680.13","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3109\/09286586.2014.884600","article-title":"Estimating community prevalence of ocular Chlamydia trachomatis infection using pooled polymerase chain reaction testing","volume":"21","author":"Ray","year":"2014","journal-title":"Ophthalmic Epidemiol"},{"key":"2020050713011097000_102.5.680.14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0002415"},{"key":"2020050713011097000_102.5.680.15","doi-asserted-by":"publisher","DOI":"10.1086\/424747"},{"key":"2020050713011097000_102.5.680.16","doi-asserted-by":"publisher","DOI":"10.1001\/jama.295.10.1142"},{"key":"2020050713011097000_102.5.680.17","doi-asserted-by":"crossref","first-page":"e1983","DOI":"10.1371\/journal.pntd.0001983","article-title":"The easiest children to reach are most likely to be infected with ocular Chlamydia trachomatis in trachoma endemic areas of Niger","volume":"7","author":"Amza","year":"2013","journal-title":"PLoS Negl Trop Dis"},{"key":"2020050713011097000_102.5.680.18","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiu046"},{"key":"2020050713011097000_102.5.680.19","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1128\/mBio.01520-16","article-title":"Collateral Damage: detrimental effect of antibiotics on the development of protective immune memory","volume":"7","author":"Benoun","year":"2016","journal-title":"MBio"},{"key":"2020050713011097000_102.5.680.20","doi-asserted-by":"publisher","DOI":"10.1086\/341414"},{"key":"2020050713011097000_102.5.680.21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000377"},{"key":"2020050713011097000_102.5.680.22","doi-asserted-by":"publisher","DOI":"10.1086\/655697"}],"container-title":["British Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bjophthalmol-2017-310916","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,26]],"date-time":"2020-09-26T08:55:59Z","timestamp":1601110559000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjo.bmj.com\/lookup\/doi\/10.1136\/bjophthalmol-2017-310916"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,11]]},"references-count":22,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2018,4,19]]},"published-print":{"date-parts":[[2018,5]]}},"alternative-id":["10.1136\/bjophthalmol-2017-310916"],"URL":"https:\/\/doi.org\/10.1136\/bjophthalmol-2017-310916","relation":{},"ISSN":["0007-1161","1468-2079"],"issn-type":[{"type":"print","value":"0007-1161"},{"type":"electronic","value":"1468-2079"}],"subject":[],"published":{"date-parts":[[2017,9,11]]}}}